Protara Therapeutics Book Value Per Share vs. Debt To Equity
| TARA Stock | USD 3.04 0.10 3.40% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 6.02956491 | Current Value 5.73 | Quarterly Volatility 502.73200177 |
For Protara Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Protara Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Protara Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Protara Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Protara Therapeutics over time as well as its relative position and ranking within its peers.
Protara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Protara Therapeutics Debt To Equity vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Protara Therapeutics's current stock value. Our valuation model uses many indicators to compare Protara Therapeutics value to that of its competitors to determine the firm's financial worth. Protara Therapeutics is currently regarded as top stock in book value per share category among its peers. It is rated below average in debt to equity category among its peers fabricating about 0.01 of Debt To Equity per Book Value Per Share. The ratio of Book Value Per Share to Debt To Equity for Protara Therapeutics is roughly 130.70 . At present, Protara Therapeutics' Book Value Per Share is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protara Therapeutics' earnings, one of the primary drivers of an investment's value.Protara Debt To Equity vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Protara Therapeutics |
| = | 6.01 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Protara Therapeutics |
| = | 0.05 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Protara Debt To Equity Comparison
Protara Therapeutics is currently under evaluation in debt to equity category among its peers.
Protara Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Protara Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Protara Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Protara Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Protara Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -31 K | -32.5 K | |
| Operating Income | -43.6 M | -45.8 M | |
| Net Loss | -69.2 M | -65.7 M | |
| Income Before Tax | -40.4 M | -42.4 M | |
| Non Operating Income Net Other | 235.8 K | 224 K | |
| Total Other Income Expense Net | 3.2 M | 3.4 M | |
| Net Loss | -59.4 M | -56.4 M | |
| Net Loss | -40.4 M | -42.4 M | |
| Income Tax Expense | -341 K | -323.9 K | |
| Interest Income | 3 M | 3.1 M | |
| Net Interest Income | 2.9 M | 3 M | |
| Change To Netincome | 44.5 M | 46.7 M | |
| Net Loss | (3.57) | (3.75) | |
| Income Quality | 0.93 | 1.13 | |
| Net Income Per E B T | 0.88 | 0.79 |
Protara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Protara Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Protara Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Protara Therapeutics' important profitability drivers and their relationship over time.
Use Protara Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Protara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protara Therapeutics will appreciate offsetting losses from the drop in the long position's value.Protara Therapeutics Pair Trading
Protara Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Protara Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Protara Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Protara Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Protara Therapeutics to buy it.
The correlation of Protara Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Protara Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Protara Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Protara Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Protara Therapeutics position
In addition to having Protara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency ETFs Thematic Idea Now
Cryptocurrency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Cryptocurrency ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
To fully project Protara Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Protara Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Protara Therapeutics' income statement, its balance sheet, and the statement of cash flows.